Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 35Lung Neoplasms 13Neoplasm Metastasis 6Stomach Neoplasms 3Thymoma 2Non-small Cell Lung Cancer Metastatic 2Biliary Tract Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Sarcoma, Alveolar Soft Part 1Recurrence 1Mesothelioma, Malignant 1Mesothelioma 1Liver Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Carcinoma 1

Interventions

Trastuzumab 2Nivolumab 2trastuzumab deruxtecan 1tocilizumab 1tipifarnib 1pembrolizumab 1entinostat 1Thalidomide 1Ramucirumab 1Methods 1Lenalidomide 1Ipilimumab 1Interleukin-12 Subunit p35 1Interleukin-12 1Immunoglobulin G 1Gemcitabine 1Fentanyl 1Early Intervention, Educational 1Docetaxel 1Disulfides 1Carboplatin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urethral Neoplasms × Ramucirumab × Thoracic × Clear all
NCT02443324 2024-07-31

A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer

Eli Lilly and Company

Phase 1 Completed
175 enrolled 23 charts
GastrointestinalGenitourinaryThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡